Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liposomal Doxorubicin Hydrochloride and Apatinib in Combination with Camrelizumab for the First-line Treatment of Advanced/unresectable Dedifferentiated Liposarcoma

NCT06694324 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06694324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06694324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liposomal Doxorubicin Hydrochloride and Apatinib in Combination with Camrelizumab for the First-line Treatment of Advanced/unresectable Dedifferentiated Liposarcoma
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2024
Completion date
December 1, 2026
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dedifferentiated liposarcoma, soft tissue sarcoma (sts)